This year, BIO-Europe, Europe’s leading partnering event for the entire biotech ecosystem, will take place in Vienna. From 3 to 5 November, the industry’s most important decision-makers will meet here to negotiate partnerships, contracts and financing, and to learn about the latest developments and trends. With over 5,700 participants from 60 countries, 2025 is set to see a record number of delegates, sponsors, exhibitors and presenting companies.
Novartis acquires Avidity Biosciences for US$12bn
Latest NewsIn a major bet on RNA medicine, Swiss Novartis AG announced to buy Avidity Biosciences Inc for US$12bn. Avidity’s Oligonucleotide Conjugate (AOC) platform allows Transferin receptor-targeted RNA delivery to muscle. With the acquisition Novartis secures access to three late-stage RNA drug candidates for muscular dystrophies.
GHO Capital expands healthcare reach with €2.5bn Fund IV close
Latest NewsGHO Capital has closed its fourth fund, GHO Capital IV LP, raising over €2.5bn (~US$2.9bn) to invest in global healthcare. The fund brings the firm’s total assets under management to around €9bn, making it Europe’s largest healthcare-focused private equity firm.
Hemab Therapeutics bags US$157m in Series C financing
Latest NewsHemab Therapeutics A/S has completed an oversubscribed US$157m Series C financing round led by Sofinnova Partners to accelarate and expand its pipeline in bleeding disorders and thrombosis treatments.
Celonic’s Strategic Alliance in ADCs
Sponsored PublicationsThe Celonic Group and CARBOGEN AMCIS AG have formed a strategic alliance to offer a fully integrated Antibody Drug Conjugate (ADC) development and manufacturing platform. This partnership combines Celonic’s biologics expertise with CARBOGEN AMCIS’s payload synthesis and conjugation capabilities, creating a seamless, end-to-end solution for ADC developers.
Vienna: The centre of the European biotech world
Sponsored PublicationsThis year, BIO-Europe, Europe’s leading partnering event for the entire biotech ecosystem, will take place in Vienna. From 3 to 5 November, the industry’s most important decision-makers will meet here to negotiate partnerships, contracts and financing, and to learn about the latest developments and trends. With over 5,700 participants from 60 countries, 2025 is set to see a record number of delegates, sponsors, exhibitors and presenting companies.
Ultra-low freezer for intensive use
ProductsSafeguarding temperature-sensitive materials is critical, and Ultra-Low Freezers (ULTs) ensure sample integrity at very low temperatures. Today’s customers demand not just reliability, but also sustainability under intensive use. The new U701V from B Medical Systems, with variable-speed technology, delivers the perfect balance: uncompromised performance, reliability, and sustainability.
US-policy-made challenges for the bio-pharma sector
BackgroundNew developments under the current U.S. administration may be a challenge for the pharma/biotech industry: the Inflation Reduction Act, Orange Book Challenges, Most Favored Nation Policy, and the new Trump-Lutnick Patent Tax. And it will likely affect European pharma and biotech.
European biotech back on stage
OpinionAfter two challenging years marked by rising interest rates and frozen capital markets, European biotech is back in the spotlight. The catalyst? Late-stage clinical success.
Synbio alliance strengthens EU corticosteroid supply chain
Latest NewsThe French AI-synbio specialist Abolis Biotechnologies SAS has entered a strategic €140m alliance with API manufacturer EuroAPI SA under the IPCEI Med4Cure funding programme. Within the collaboration, Abolis is developing production chassis for microbial corticosteroid manufacturing. The goal: to make Europe independent from imports from Asia.
Meeting global market challenges
Sponsored PublicationsThe global biologics industry is entering a new phase of maturity. As costs tighten and timelines accelerate, CDMOs must deliver uncompromised quality while driving efficiency. Rezon Bio, an EU-based biologics CDMO with state-of-the-art facilities and a client-centric approach, was established to meet biotech and pharmaceutical client needs with agility, pragmatism, and trust.